Analysis: What’s behind the Trump Administration’s push on price disclosure in healthcare
The Trump administration is looking to price transparency initiatives to help strengthen the President’s resume on healthcare given that healthcare remains a key issue for voters across the political spectrum.
How providers can finance, profit from programs to tackle social determinants
Hospital and finance leaders have heard much about the theoretical benefits of addressing the social determinants of health (SDOH). But some have found ways to fund such activities — and get an ROI.
Analysis: What to expect after the initial release of draft “surprise bill” legislation
What might providers expect next given the recent release of bi-partisan drafts of bills aimed at relieving the consumer burden of surprise bills?
Reconsidering post-acute care options
HFMA President and CEO Joe Fifer highlights the need to consider post-acute care in the context of reducing the total cost of care.
8 Tips for Long-Range Cost Savings in Healthcare Construction
Savvy project management can reduce construction costs and improve patient satisfaction.
Chronic Disease Most Significant Factor in Care Cost Variation
A recent study by HFMA and other partners revealed the factors that impact total cost of care.
April 22-26: See what events are coming in healthcare
Stay ahead of healthcare news and developments with this listing of hearings, conferences, webinars, contests, public forums and deadlines for the week of April 22.
May 6-10: See what events are coming in healthcare
Stay ahead of healthcare news and developments with this listing of hearings, conferences, webinars, contests, public forums and deadlines for the week of May 6.
Rising healthcare costs to spur little action before 2020, analysts say
Affordability concerns are impacting the healthcare of a growing number of Americans, according to new polling. However, there is little chance that Congress will address that issue before the 2020 election, political analysts say.
Geisinger clinical effectiveness program credited with stabilizing biologics costs
Biologics comprised less than 1% of Geisinger Health’s claims but were approaching 50% of its total drug spending. That is, until a comparative effectiveness program halted the rapid increase.